Diseases with which we struggle
Целевые терапевтические показания платформы
Vision loss
We target diabetic retinopathy (DR) and age-related macular degeneration (ARM). DR, or diabetic eye disease, is a leading cause of blindness. It affects up to 80 percent of people who have had diabetes for 20 years or more. DR accounts for 12% of all new cases of blindness. ARM is a relatively common eye disease and is the leading cause of severe vision loss in people 65 years or older. In 2015 it affected 6.2 million people globally
Peripheral Artery Disease & Critical Limb Ischemia (CLI)
The Problem: Severe arterial occlusion causing a critical deficit in distal limb perfusion. Annually, over 1.5 million individuals suffer from advanced vascular disease in the region, with more than 144,000 cases deteriorating into CLI. This leads to 30,000–40,000 emergency amputations due to the complete lack of safe, functional pro-angiogenic therapies
Our Solution: Angiogenocept (Dll4-Fc). An engineered truncated protein that eliminates systemic Notch toxicities to induce local, functional capillary branching and restore downstream tissue oxygenation
Cardiovascular Disease
Cardiovascular disease is a global public health problem contributing to 30% of global mortality and 10% of the global disease burden. In 2005, from a total of 58 million deaths worldwide, 17 million were due to cardiovascular disease and, among them, 7.6 million were due to coronary heart disease
Solid Tumors & Colorectal Cancer (CRC)
The Problem: Colorectal cancer represents a massive global burden with over 600,000 new cases diagnosed annually. Due to late-stage diagnostics, 1-year mortality rates approach 40%. Traditional therapies are hindered by severe systemic toxicity and tumor resistance
Our Solution: PDGFRα-hFc. A highly selective protein trap that starves tumor vasculature and stalls metastasis by blocking stromal cell signaling, bypassing the severe multi-kinase toxicities of chemical inhibitors (TKIs)
Stroke
Stroke is a situation when blood flow to the brain results in cell death, causing part of the brain not functioning properly. In 2015, stroke was the second most frequent cause of death after coronary artery disease, accounting for 6.3 million deaths (11% of the total). About 11 million deaths resulted stroke. About half of people who have had a stroke live less than one year
Fibrotic Disorders & Autoimmune Diseases
The Problem: Chronic inflammation triggered by hyperactivation of TNFα, IL-1, and IL-6 inevitably drives irreversible organ scarring (liver cirrhosis, pulmonary fibrosis) and severe systemic degradation (rheumatoid arthritis, gout). Current biologics require frequent, painful dosing and often trigger neutralising anti-drug antibodies (ADA)
Our Solution: TNFR1-hinge-Fc, IL-1RA-hFc, and IL-6R-hFc. Ultra-safe cytokine traps featuring optimized linkers that eliminate immunogenicity risks while extending plasma half-life to enable a patient-friendly once-monthly dosing regimen
Advanced Rheumatoid Arthritis & Severe Uveitis
The Problem: Autoimmune destruction of joint cartilage and ocular tissues driven by hyperactivation of Tumor Necrosis Factor-alpha (TNFα). Existing standard-of-care monoclonal antibodies are limited by high systemic multi-dose toxicity, escalating production costs, and the rapid development of neutralizing anti-drug antibodies (ADA) that cause patient resistance
Our Solution: TNFR1-hinge-Fc. A high-affinity recombinant receptor antagonist utilizing an optimized structural hinge region. It enables the receptor and the Fc-domains to operate independently, delivering a nanomolar binding affinity (~1 nM) that safely suppresses joint inflammation during long-term therapy
Colorectal cancer
Colorectal cancer, also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). A cancer is the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Globally, colorectal cancer is the third most common type of cancer, making up about 10% of all cases. In 2012, there were 1.4 million new cases and 694,000 deaths from the disease
Critical limb ischaemia
Critical limb ischemia, also referred to as limb threat, is an advanced stage of peripheral artery disease. It is defined as a triad of ischemic rest pain, arterial insufficiency ulcers, and gangrene. More than 100 million people are suffering from the disease. It has a negative prognosis within a year after the initial diagnosis, with 1-year amputation rates of approximately 12% and mortality of 50% at 5 years and 70% at 10 years
Cytokine Release Syndrome (CRS) & Gouty Flares
The Problem:Acute, life-threatening hyperinflammatory responses—such as Cytokine Release Storms (CRS) induced by systemic infections and acute gouty arthritis—driven by the uncontrolled release of Interleukin-1 (IL-1α and IL-1β). Standard flexible peptide linkers (e.g., GGGGS repeats) in early-generation fusion proteins carry high structural risks of aggregate formation and severe immunogenicity
Our Solution: IL-1RA-hFc. An ultra-safe, engineered interleukin receptor antagonist configured with a proprietary, ultra-short rigid RS-linker. This architecture eliminates the risk of neo-epitope creation and cross-reactivity, ensuring high therapeutic safety and an extended plasma half-life for monthly dosing
Rheumatoid arthritis
Rheumatoid arthritis is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. It affects about 24.5 million people as of 2015. In 2013, it resulted in 38,000 deaths up from 28,000 deaths in 1990
